

## NIH Public Access

**Author Manuscript** 

Published in final edited form as:

Mol Pharm. 2010 December 6; 7(6): 2240-2254. doi:10.1021/mp100233v.

### Structural Determinants for Transport Across the Intestinal Bile Acid Transporter Using C-24 Bile Acid Conjugates

Rana Rais<sup>†,‡</sup>, Chayan Acharya<sup>†,‡</sup>, Alexander D. MacKerell Jr.<sup>‡,\*</sup>, and James E. Polli<sup>‡,\*</sup> <sup>‡</sup>Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, Baltimore, MD 21201

#### Abstract

The human apical sodium dependent bile acid transporter (hASBT) re-absorbs gram quantities of bile acid daily and is a potential prodrug target to increase oral drug absorption. In the absence of a high resolution hASBT crystal structure, 3D-QSAR modeling may prove beneficial in designing prodrug targets to hASBT. The objective was to derive a conformationally sampled pharmacophore 3D-QSAR (CSP-SAR) model for the uptake of bile acid conjugates by hASBT. A series of bile acid conjugates of glutamyl chenodeoxycholate were evaluated in terms of  $K_m$  and normalized V<sub>max</sub>(normV<sub>max</sub>) using hASBT-MDCK cells. All mono-anionic conjugates were potent substrates. Dianions, cations and zwitterions, which bound with a high affinity, were not substrates. CSP-SAR models were derived using structural and physicochemical descriptors, and evaluated via cross-validation. The best CSP-SAR model for  $K_m$  included two structural and two physiochemical descriptors, where substrate hydrophobicity enhanced affinity. A best CSP-SAR model for  $K_m$ /norm $V_{max}$  employed one structural and three physicochemical descriptors, also indicating hydrophobicity enhanced efficiency. Overall, the bile acid C-24 region accommodated a range of substituted anilines, provided a single negative charge was present near C-24. In comparing uptake findings to prior inhibition results, increased hydrophobicity enhanced activity, with dianions and zwitterions hindering activity.

#### Keywords

bile acid; transporter; substrate; Michaelis-Menten; affinity; capacity; hydrophobicity; structureactivity relationship

#### Introduction

The human apical sodium dependent bile acid transporter (SLC10A2, hASBT) is the major transporter involved in uptake and transport of bile acids from the intestine. It also plays an important role in the enterohepatic circulation of bile acids, enabling efficient recycling and conservation of bile acids to maintain the bile acid pool in the body 1<sup>-4</sup>. The transport of both conjugated and unconjugated bile acids with over 95% efficacy emphasizes hASBT's tremendous potential as a prodrug target 5. The design of successful prodrug targets to hASBT is impeded by a lack of understanding of the molecular mechanisms of uptake, and

<sup>&</sup>lt;sup>\*</sup>Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, HSF2 Room 623, Baltimore, MD 21201, Telephone: 410-706-8292, Fax: 410-706-5017 jpolli@rx.umaryland.edu. Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, HSF2 Room 629, Baltimore, MD 21201, Telephone: 410-706-7442, Fax : 410-706-5017 amackere@rx.umaryland.edu. <sup>†</sup>Contributed equally to the work

Supporting Information (SI): LC/MS/MS conditions and computational tables for all synthesized analogues. This material is available free of charge via the internet at http://pubs.acs.org.

the absence of a high resolution crystal structure. Consequently, there is a need to identify the important structural and functional characteristics that underlie the transport mechanisms for successful prodrug targeting of hASBT. Despite the extensive studies on the functional and molecular properties hASBT and its interactions with various bile acid analogues, an understanding of the substrate requirements for hASBT is limited. In particular, the influence of the C-24 chemistry space attributes that enhance or impede interaction of bile acid analogues with hASBT are not clear 6. Notably, no 3D-QSAR uptake model has been developed for hASBT substrates.

Prior to cloning of hASBT, Lack et al. demonstrated conjugation improved transport efficacy and proposed that a negative charge around the C-24 region is essential for interaction with hASBT 7. Most studies further established that a single negative charge around C-24 was important for transport activity. For instance, Swaan and colleagues examined the transport of four C-24 bile acid conjugates across Caco-2 monolayers, each providing a negative charge near C-24, of which two conjugates were rapidly transported 8. Further analysis suggested the length of the C-24 side chain can be 14 Å or longer for translocation, and that large hydrophobic moieties enhanced binding to hASBT. Baringhaus et al. developed a 3D-QSAR inhibition model with a set of 17 inhibitors of the rabbit ileal Na /bile acid cotransporter. The developed pharmacophore included five essential features: one hydrogen bond donor, one hydrogen bond acceptor and three hydrophobic features.9 Previously, in our laboratory, native and C-24 modified bile acid conjugates were studied in stably transfected hASBT-MDCK monolayers. These studies suggested the natural bile acid chenodeoxycholic acid (CDCA) can be coupled to glutamic acid as a linker (denoted glu-CDCA) in order to maintain a single negative charge around C-24, to which various probes can be conjugated 6, 10. Additionally, acyclovir bioavailability was increased by conjugating acyclovir to CDCA via a valine linker at the bile acid's C-24 position, demonstrating negative charge could be replaced by a hydrogen bond accepting group 8.

The conformationally sampled pharmacophore (CSP) method is a novel approach 11<sup>-14</sup> that can be combined with physiochemical parameters to yield 3D-QSAR models (denoted CSP-SAR). CSP is well suited for compound classes with high structural flexibility, such as bile acid conjugates. CSP considers all accessible molecular conformations to assure that the bioactive conformer of each compound is included for model development. The inhibition requirements of hASBT using anilinyl conjugates of glu-CDCA 15 and aminopiperidine conjugates were studied previously using CSP-SAR 14. In this study, we focus on delineating the uptake requirements of hASBT using a previously reported series of glu-CDCA conjugates of benzene and aminopiperidine analogues 14<sup>,</sup> 15, where benzene and aminopiperidine represent drug scaffolds. Transport data in these bile acid analogues were used to build a CSP-SAR model that could be of utility to predict potential prodrugs, where CDCA would be conjugated to the drug via a glutamic acid linker. Overall, this work attempts to elucidate hASBT substrate requirements and derive 3D-QSAR uptake models, which have promised to develop a rational prodrug design strategy to target ASBT.

#### **Experimental Section**

#### **Materials**

 $[^{3}H]$ -Taurocholic acid (10 µCi/mmol) was purchased from American Radiolabeled Chemicals, Inc (St. Louis, MO). Taurocholate was obtained from Sigma Aldrich (St. Louis, MO). CDCA was obtained from TCI America (Portland, OR). Geneticin, fetal bovine serum (FBS), trypsin, and DMEM were purchased from Invitrogen (Rockville, MD). All other reagents and chemicals were of the highest purity commercially available.

#### Synthetic Procedures

A series of substituted anilinyl 15 and aminopiperidine conjugates glu-CDCA were previously synthesized 14. Briefly, almost all conjugates employed coupling  $\alpha$ -benzyl glutamic acid to CDCA via either N-hydroxysuccinimide (OSU) ester or benzotriazole (OBT) ester. Various substituted probes were then coupled to bile acid via glutamic acid by stirring either at RT or 60°C using O-benztriazol-1-yloxytris-1,1,3,3 tetra methyl uranium hexaflourophosphate (HBTU) as the activating agent and triethylamine (TEA) as the base. The resulting neutral compounds were then subjected to hydrogenation in a parr shaker for 1–2 h in ethanol and 10% palladium to remove the  $\alpha$ - benzyl group, yielding the mono and dianionic targets. Neutral compound intermediates were purified by column chromatography using a gradient of hexane and ethyl acetate. Final target compounds were obtained as solids after deprotection. Identity and purity were confirmed by TLC, MS, NMR, and elemental analysis 15.

#### **Cell Culture**

Stably transfected hASBT-MDCK cells were cultured as described previously 10<sup>,</sup> 16. Briefly, cells were grown at 37°C, 90% relative humidity, and 5% CO<sub>2</sub> atmosphere and fed every 2 days. The media for cell culture comprised DMEM supplemented with 10% FBS, 50 U/mL penicillin, and 50  $\mu$ g/mL streptomycin. Geneticin at 1 mg/mL was used to maintain selection pressure. Cells were passaged every 4 days or after reaching 90% confluence.

#### Conjugate uptake into hASBT-MDCK cells

Uptake studies of 32 conjugates of glu-CDCA were performed in 12-well cell culture polystyrene plates (Corning Costar; Corning, NY). Of the 32 conjugates, 29 were anilinyl conjugates of glu-CDCA 15, that were either mono- or di-anionic, while three were aminopiperidinyl conjugates of glu-CDCA 14. Aminopiperidinyl conjugates were either cationic or zwitterionic. The 12-well plates were seeded with hASBT-MDCK cells at a density of  $1.5 \times 10^6$  cells/well and induced on day 4 with 10 mM sodium butyrate for 12–15 h prior to uptake experiments. Conjugate concentration varied from 0-100 µM for most monoanions and up to 5000  $\mu$ M for dianions. Uptake studies were initiated by washing the cells three times with warm Hank's balanced salt solution (HBSS) [pH 6.8] and exposing cells to donor solution for 10 min at 37°C and 50 rpm in an orbital shaker. Cells were washed three times with chilled sodium free buffer. Parallel identical studies were performed without sodium, in order to measure passive conjugate uptake. Additionally, taurocholate  $V_{max}$  was measured on each occasion as previously described 14, as taurocholate is a reference hASBT substrate. For each conjugate, conjugate  $V_{max}$  was normalized to observed taurocholate  $V_{max}$  to yield substrate normalized  $V_{max}$ , denoted norm $V_{max}$ . norm $V_{max}$  accommodates variable hASBT protein expression across occasions.

#### Quantification of conjugates by LC/MS/MS

Cells were lysed and subjected to extraction as described previously 17. Briefly, at the end of uptake experiment, cells were lysed by addition of 300  $\mu$ L of acetonitrile. Acetonitrile was evaporated at RT over 2–3 hr. Extraction of conjugate from cell lysate was performed by adding 1mL of 50:50 acetonitrile:water spiked with 500 nM internal standard; plates were then sealed with parafilm. After 30 min, extract was placed into silanized vials and stored in  $-80^{\circ}$ C until analyzed. Recovery experiments using the extraction protocol have been previously described using <sup>3</sup>[H]-taurocholate as a standard substrate for hASBT 17. Taurocholate uptake studies were performed as a standard control; taurocholate kinetic parameters were determined from LC/MS/MS analysis using the methods described below except detection was achieved under negative ion electrospray tandem MS using the [M-

H]<sup>-</sup>, peaks and compound **1** as the internal standard. The multiple reaction monitoring (MRM) transition used for taurocholate was 514.4> 123.66 and run time was 8 min.

Conjugate uptake was quantified by LC/MS/MS using a Finnigan Surveyor HPLC system equipped with an autosampler with a Finnigan TSQ quantum Discovery Max mass spectrometer (Thermo Fisher Scientific Inc., Waltham MA). The column was a Phenomenex Luna C8,  $50 \times 2$  mm,  $5\mu$  column, heated to  $40^{\circ}$ C. The flow rate was 0.4 mL/min. The gradient of 5–95% acetonitrile was employed over 0.2–4 min and the overall run time for most conjugates was 6-8 min. The starting mobile phase gradient for most conjugates was 50:50 acetonitrile: water (Table S1a in supplemental data) up to 0.2 min, followed by increase in organic phase to 95% up to 3-4 min. It was maintained at 95% organic phase for 1 min and then reduced back to 50% organic phase by 6-8 min. The mobile phase included 0.1% formic acid as a modifier for all monoionic and dianionic conjugates. For zwitterionic and cationic conjugates, 0.1% ammonium hydroxide was used as the modifier. Injection volume was  $10 \,\mu$ L. Detection was achieved under positive ion electrospray tandem MS using the  $[M+H]^+$  peak, as positive mode provided the greatest sensitivity, except for the standard taurocholate where detection was achieved under negative ion mode. The unsubstituted aniline conjugate, which shares a structure similar to all studied conjugates, was used as the internal standard. MRM transitions for the conjugates are listed in Table S1a.

#### **Kinetic Analysis**

Conjugate kinetic parameters  $V_{max}$ ,  $K_m$  and  $P_p$  were obtained by fitting uptake data to modified the Michaelis-Menten model as previously described using WinNonlin 5.2 (Pharsight, Mountain View, CA) 17. Eqn 1 is a modified version of the classical Michaelis-Menten which accounts for the presence of an apical boundary layer,  $P_{ABL}$  was  $1.5 \times 10^{-4}$  cm<sup>2</sup>/s 18. Data from sodium free studies were fitted to eqn. 2 which represents the passive transport.

$$J = \frac{P_{ABL} \left(\frac{V_{max}}{K_m + S} + P_p\right)}{P_{ABL} + \frac{V_{max}}{K_m + S} + P_p} S$$
(1)

$$J = \frac{P_{ABL} P_p S}{P_{ABL} + P_p}$$
(2)

#### **Computational Methods**

The twenty-seven anilinyl conjugates of glu-CDCA that were substrates were used to develop CSP-SAR substrate models, individually for  $K_m$  and  $K_m$  /norm $V_{max}$ . None of the aminopiperidine conjugates were substrates, and hence not used in CSP-SAR analysis.  $K_m$  reflects substrate affinity for the transporter.  $K_m$  values less than 0.1 µM were assigned a value of 0.1 µM, due to the limited ability to accurately estimate potent  $K_m$  values 18.  $V_{max}$  is the transporter capacity for the substrate. norm $V_{max}$  is  $V_{max}$  normalized against observed taurocholate  $V_{max}$  in order to accommodate variable hASBT protein expression across occasions.  $K_m$ /norm $V_{max}$  describes the reciprocal of the transporter efficiency. Model development for norm $V_{max}$  and norm $V_{max}/K_m$  were not successful, as described below.

Compound descriptors for CSP-SAR modeling were previously generated 15. Briefly, *in silico* models of conjugates were built using the program CHARMM 19 with the all-atom

CHARMM general force field (CGenFF) 20 . Each molecule was subjected to 1000 steps of steepest descent (SD) and 500 steps of Newton-Raphson (NRAP) energy minimization in the gas phase to a gradient of 10<sup>-4</sup> kcal/mol/Å. Structures minimized using CHARMM were subjected to replica exchange molecular dynamic (MD) simulations involving 20 ns simulations with four replicas of each molecule between 300K and 400K, using an exponential scale (300K, 330K, 363K, and 400K) 21<sup>-23</sup>. Exchange of replicas was attempted after every 250 MD steps. MD simulations were performed using Langevin dynamics 24 with an integration time step of 0.002 ps and the aqueous solvation was modeled implicitly via the Generalized Born Continuum Solvent Model (GBMV) 25, 26. SHAKE was applied to all covalent bonds involving hydrogens 27. Conformations saved every 20 ps and obtained from all 4 replicas were used for the analysis. The protonation states of the ionizable groups present in the molecules were determined based on the experimental pH of 6.8. All free acids were assumed to be protonated.

As previously reported, several physico-chemical descriptors were calculated for each conjugate by averaging over the full trajectories 15. Those descriptors that manifested here in models are briefly described here. The free energy of solvation of each compound in water ( $\Delta G_w$ ) was calculated using the semi-empirical quantum chemical program AMSOL6.8 by invoking the AM1-SM5.42R continuum solvent model 28.  $\Delta G_w$  was calculated by taking the difference between the heat of formation plus solvation energy of the solvated system in its relaxed electronic state and that for the gas-phase system. Average solvent accessible surface area (SASA) and polar surface area (PSA) were calculated using the Lee and Richards method as implemented in CHARMM 29. The radius of the solvent molecule was taken as 1.4 Å, which approximates the radius of a water molecule 30. PSA for each compound was calculated by adding the contribution of polar atoms (N, O, F, Cl, Br and hydrogen atoms covalently attached to any of these atoms). For calculation of PSA, halogens were included as they could potentially take part in polar interactions with other polar atoms 31<sup>-34</sup>. SASA and PSA were also calculated exclusively for the region beyond C-24 of the bile acid conjugates (SASAside and PSAside) to access the contribution of the substituents alone towards the interaction with hASBT. Surface area terms were obtained as averages over the conformations saved from the MD simulations. Molar refractivity (MR) and flexibility parameter (KierFlex) were calculated using the program MOE 35. The number of hydrogen bond donors (HD) for each molecule was calculated using Discovery Studio (Accelrys Inc.) 36.

Conformational properties of molecules required for CSP model development included the 20 pharmacophore distances and 26 pharmacophore angles reported previously 15 as shown in Figure 1. Overlap coefficients (OC) for each compound were calculated with respect to the most potent substrate in the data set (Compound **13**,  $K_m = 0.1 \mu$ M). Greater OC values reflect greater structural similarity to the most potent compound.

#### **Regression Analysis**

Using the statistical program  $\mathbf{R}$ , regression analysis was applied to each  $K_m$  and  $K_m$ / norm $V_{max}$  to develop CSP-SAR substrate models. Molecular descriptors were subjected to single variable as well as multivariable regression against each of the dependent variables. The structural and physico-chemical descriptors were then combined to make a complete set of molecular descriptors for model development. All molecular descriptors were subjected to multivariable regression analysis against both  $K_m$  and  $K_m$ /norm $V_{max}$  separately.

Molecular descriptors were subjected to multivariable regression in all possible combinations of two. However, any combination having correlation between each other (*r*) greater than 0.8 were not considered. Table S2 (supplemental data) lists correlation values between independent descriptors. All combinations of descriptors with p-values of the

Mol Pharm. Author manuscript; available in PMC 2011 December 6.

independent variables, as well as the intercept, less than 0.05 were selected for further analysis. Additional descriptors were sequentially added to each selected pair of descriptors. This approach was applied until all possible combinations of descriptors yielded *p*-values greater than 0.05. All combinations of descriptors with *p*-values less than 0.05 formed the set of candidate models. The standardized coefficients of the independent variables 37 of the candidate models were also calculated 38, as previously described 15. Model evaluation was performed using the modified Akaike Information Criterion (AIC<sub>C</sub>) 39, 40 analysis and leave-one-out cross validation method, as described previously 14, 15. In calculating AIC<sub>C</sub>, the residual sum of squares (RSS) obtained from fitting all compounds.

#### **Results and Discussion**

Results from uptake experiments into hASBT-MDCK cells are presented, followed by CSP-SAR substrate models. CSP-SAR models are for substrate affinity (i.e.  $K_m$ ) and for reciprocal of efficiency (i.e.  $K_m$ /norm $V_{max}$ ).

#### Conjugate uptake into hASBT-MDCK cells

A congeneric series of 32 aniline and aminopiperidine bile acid conjugates previously synthesized and tested for hASBT inhibition 15 were evaluated for uptake by hASBT. Figure 2 shows the uptake profiles of taurocholate ( $K_m$ = 4.84 µM and  $V_{max}$ = 0.699 pmol/cm<sup>2</sup>/s) which is a known potent substrate, and the unsubstituted anilinyl conjugate of glu-CDCA (compound 1). Compound 1 kinetics was similar to taurocholate. Like taurocholate, compound 1 was a potent hASBT substrate ( $K_m$ = 0.823 µM and norm $V_{max}$ = 1.19). Total uptake (in presence of sodium) was markedly higher than passive uptake (absence of sodium).

Kinetics of hASBT-mediated transport was assessed for each conjugate from transport studies employing a range of donor concentrations for each conjugate. Table 1 lists 27 compounds (compounds 1–27) that were hASBT substrates. Table S1b (supplemental data) provides stereochemical SMILES of the compounds used in this study. All were monoanionic, except one dianionic compound. Table 2 lists five compounds (compounds **28–32**) that were not hASBT substrates, and includes two dianions, one cation, and two zwitterionic compounds. Tables 1 and 2 indicate compound kinetic parameters  $K_m$ , norm $V_{max}$ , and  $P_p$ . Mono-anionic conjugates were potent substrates of hASBT with activity ranging from  $0.1\mu$ M to  $17 \mu$ M. This  $K_m$  range is the same as the range for native bile acids, which is from <0.1 to 16  $\mu$ M 41. These results suggest the potential of further exploiting C-24 conjugation to design prodrugs that can be targeted to hASBT. Among the substrates, ring substituents varied in electronic character, size, and hydrophobicity. Increased polarity led to a slight decrease in affinity (i.e. increase in  $K_m$ ) as seen by esters, amine and boc group substituents on the benzene ring. Electronic character did not significantly impact affinity, as electron donating (e.g. methyl, methoxy) and electron withdrawing substituents (e.g. chloro, flouro) were potent substrates.

Regarding compound charge, substrate results differed from inhibition results. For inhibition, a single negative charge was not an essential requirement 6. However, charge played the dominant role in translocation across hASBT. Only monoanions were potent substrates. Compared to other monoanions, the location of the negative charge was moved distal from C-24 to the benzene ring by protecting the  $\alpha$ -acid on glutamic acid, resulting in loss of activity (compound **26**,  $K_m = 495\mu$ M). This result suggests that the negative charge should preferentially be within the vicinity of C-24 for active hASBT uptake. None of the three aminopiperidine conjugates (one cation and two zwitterions) were substrates. Only one of the three dianionic conjugates was a substrate (compound **27**), but was a very weak substrate. Previous studies have also shown that dianions are weak inhibitors of hASBT 15,

Mol Pharm. Author manuscript; available in PMC 2011 December 6.

but that cations and zwitterions bound with moderate to good affinity 6, 14. Translocation is a more elaborate and complex phenomenon than binding, such that compounds which were strong inhibitors of hASBT were not found to be strongly translocated if not bearing a single negative charge.

Figure 3 (panel A) illustrates the correlation between norm $V_{max}$  and substrate  $K_m$  for compounds 1–25. Compounds 26 and 27 were weak substrates and not included. An inverse relationship was observed where higher capacity was weakly associated with substrate affinity (i.e. lower  $K_m$ ) (linear r<sup>2</sup> = 0.391). This association points towards high binding affinity to generally promote transport capacity.

Figure 3 also plots the relationships of  $K_m$  and norm $V_{max}$  versus inhibitory  $K_i$  for compounds **1–25** (panels B and C, respectively).  $K_i$  values were reported previously 15 and reflect inhibition potency. Each  $K_m$  and norm $V_{max}$  were weakly associated with  $K_i$  (linear  $r^2 = 0.360$  for  $K_m$  and linear  $r^2 = 0.310$  for norm $V_{max}$ ). These monoanionic conjugates were potent inhibitors ( $K_i$  ranged from 0.889 to 16.3 µM) and potent substrates ( $K_m$  ranged from 0.1 to 17.5 µM).  $K_i$  and  $K_m$  values were qualitatively similar, reflecting high inhibition potency and high substrate affinity. Like native bile acids 10, these data indicate substrate binding was the rate limiting step for translocation of monoanions.

#### **Computational Modeling**

The compounds were subjected to CSP-SAR analysis.  $K_m$ , norm $V_{max}$ , norm $V_{max}/K_m$ , and  $K_m$ /norm $V_{max}$  were separately considered, with the aim to identify structural and physicochemical descriptors that explain the biological activity. Results for norm $V_{max}$  and norm $V_{max}/K_m$  did not yield predictive models. The single variable regression analysis yielded poor correlation for norm $V_{max}$  and norm $V_{max}/K_m$  (r<sup>2</sup>  $\leq$  0.3), and further fitting was not attempted. However, successful models were obtained for  $K_m$  and  $K_m$ /norm $V_{max}$  and these results are discussed below.

#### CSP-SAR hASBT Substrate Model Development: Quantitative Model

Two data sets were examined to obtain substrate CSP-SAR models. Set 1 included all compounds that were substrates, while Set 2 excluded compounds **26** and **27**. The  $K_m$  values for **26** and **27** were around 400 – 600 fold higher than that of other compounds, indicating that specific features of **26** and **27** lead to significantly lower activities. **27** was the only dianionic conjugate that showed any measurable translocation. **26** was similar to **27** except the a-acid on the glutamic acid linker was protected by the benzyl group, providing a distal charge to C-24. As shown below, these compounds dominated model fitting when included in data set (i.e. Set 1), such that the sensitivity of the model to properties of the other compounds was diminished. Table S3 (supplemental data) shows various molecular descriptor values used to describe  $K_m$  and  $K_m$ /norm $V_{max}$  of the anilinyl conjugates of glu-CDCA. Aminopiperidine conjugates were not substrates and were not considered in the model development.

#### CSP-SAR Model for K<sub>m</sub>: Single Variable Regression

For each data Set 1 and Set 2, two best CSP-SAR models for  $K_m$  were obtained. Table S4 (supplemental data) presents intermediate analysis results from single variable regression of molecular descriptors against  $K_m$  for Set 1. Table S5 (supplemental data) represents the same results for **Set 2**. Molecular descriptors included both structural (e.g. angle, distance) as well as physico-chemical descriptors where physico-chemical descriptors provided higher correlations to  $K_m$  for single variable regression.

In the single regression analysis, the physio-chemical descriptors provided higher correlations to  $K_m$  than the structural terms. For Set 1,  $\Delta G_w$  yielded the highest correlation against  $K_m$  amongst all the molecular descriptors (Table S4), while HD yielded the highest correlation with  $K_m$  for Set 2 (Table S5). LogP and SASA<sub>side</sub> yielded the second highest correlation with  $K_m$  for Set 1 and Set 2, respectively. The negative coefficients of  $\Delta G_w$  and logP for both sets indicated that increased compound hydrophobicity enhanced affinity (i.e. decreased  $K_m$ ). Consistently, HD yielded a positive coefficient for **Set 2**, further indicating that polar character reduced affinity.

Amongst the structural descriptors, OC of the angles C19-GS-O3 and O7-AA-C18 yielded the two highest correlations for Set 1. Figure 4 (panel A and B) shows the probability distributions of these two angles for compounds **13** (most potent substrate among all compounds) and **27** (weakest substrate in Set 1). All conformational descriptors, except angles GS-O3-AA and GS-O7-AA, exhibited negative linear coefficients for the OCs in **Set 1**, indicating that conformational similarity to **13** promoted lower  $K_m$  value. Angles GS-O3-AA and GS-O7-AA had positive coefficients. However, further analysis showed almost no change in the angle distributions by compounds (Table S4) and poor  $r^2$ , suggesting these descriptors were not predictive of  $K_m$ .

Structural descriptors did not yield high correlation ( $r^2 \le 0.114$ ) with  $K_m$  for **Set 2** as shown in Table S5. Figure S1 (supplemental data) shows the probability distributions of angles O7-C18-GS and O7-C19-GS for **13** (most potent substrate among all compounds) and **18** (weakest substrate in Set 2). These angles were the structural descriptors in single variable regression for Set 2 that exhibited the two best correlations with  $K_m$ , but correlations are still relatively low.

#### CSP-SAR Model for Km: Multivariable Regression

For Set 1 and Set 2, 860 and 168 candidate models, respectively, were identified via multivariable regression. Tables 3 and 4 presents the two top models for Set 1 and 2, respectively. AIC was used to rank model fit quality. The best model for Set 1 yielded  $r^2 = 0.926$  and  $Q^2 = 0.630$ , and showed 10.8% probability of being the best model. The best model Set 2 yielded  $r^2 = 0.821$  and  $Q^2 = 0.683$ , and had 13.5% probability of being the best model. The regression plots of the predicted vs. observed  $K_m$  values are drawn in Figure 5 for Set 1 and Set 2.

 $\Delta G_w$  and MR appeared in the two top models for Set 1 with negative and positive coefficients, respectively, indicating hydrophobicity favors transport affinity (Table 3). In these models, coefficients of angles O7-AA-C18 and O7-AA-BC were negative, indicating conformational similarity to **13**, promotes activity. Angle O7-AA-C18 is the spatial relationship between 7-OH,  $\alpha$ -acid, and C18; angle O7-AA-BC characterizes the spatial orientation of 7-OH,  $\alpha$ -acid, and the steroidal nucleus. Figure 4 (panel B and C) depicts the conformational distribution of these two structural descriptors for **13** and **27** (weakest substrate in Set 1). The standardized coefficients for distances BC-GS<sub>min</sub> or O7-GS<sub>min</sub>, indicated these distances had the least effect on substrate activity.

 $\Delta G_w$  appeared in 395 of the 860 candidate models for Set 1, in part due to the dianionic compound **27**. This compound's weak affinity is explained by its extreme aqueous solvation free energy. For the top two models, the standardized coefficients of  $\Delta G_w$  indicate this descriptor to be the most influential. The role of  $\Delta G_w$  in determining  $K_m$  is consistent with inhibition results for these conjugates, where  $\Delta G_w$  was also the most significant factor for binding affinity (i.e.  $K_i$ ).

The two top models for Set 2 included HD, KierFlex and  $\Delta G_w$  (Table 4). The positive coefficient of HD indicated that increased polar character diminished activity. Consistently, the negative coefficient of logP indicated hydrophobicity favors activity. The positive coefficient of KierFlex indicated that substrate flexibility disfavored affinity. The models also contained angle GS-O3-C18 or angle GS-O7-C18. Each showed negative coefficients, indicating conformational similarity to **13** promoted activity. GS-O3-C18 is the angle between the  $\gamma$ -substituent, 3-OH, and C-18, while GS-O7-C18 represents the spatial relationship between the  $\gamma$ -substituent, 7-OH, and C-18. Figure 6 (panels A and B) depicts the conformational distributions for **13** and **18** (weakest substrate in Set 2). While  $\Delta G_w$  was perhaps the dominant parameter for Set 1, in part due to compound **27** all descriptors in Set 2 contributed more equally to explain the  $K_m$  data, as judged by the similar magnitude coefficients. The predicted  $K_m$  values of the conjugates in both sets using their respective best model are shown in Table S8 (supplemental data).

Figure 7 presents representative conformers for compounds 13, 18, and 27, (red, blue, and green, respectively). The relative orientation of 27 (weakest substrate) is distinctly different from 13 (most potent substrate). Compound 18 is the least potent substrate in Set 2 and was more similar to 13 than was 27.

#### CSP-SAR Model for K<sub>m</sub>/norm V<sub>max</sub>: Single Variable Regression

 $K_m$ /norm $V_{max}$  describes the reciprocal of the transporter efficiency. The more familiar form norm $V_{max}/K_m$  reflects transporter efficiency, but was not successfully modeled.Compared to  $K_m$ /norm $V_{max}$ , norm $V_{max}/K_m$  was not successful due to the regression effects of assigned  $K_m = 0.1 \ \mu$ M to the most potent substrates, as  $K_m$  is in the denominator of norm $V_{max}/K_m$  but not K<sub>m</sub>/norm $V_{max}$ .

Interestingly, single variable regression results for  $K_m$ /norm $V_{max}$  were similar to such results for  $K_m$ .  $\Delta G_w$  yielded the highest correlation in Set 1 (Table S6 in supplemental data), while HD yielded the highest correlation for Set 2 (Table S7). logP and SASA<sub>side</sub> yielded the second highest correlation with  $K_m$ /norm $V_{max}$  for Set 1 and 2, respectively. For each  $\Delta G_w$ , logP, and HD, compound hydrophobicity favored efficiency. The positive coefficient of SASA<sub>side</sub> indicates that bulky groups beyond C-24 region disfavors activity, in agreement with prior findings 6. OCs of the angles C19-GS- O3 and O7-C19-GS yielded the two highest correlations amongst the structural descriptors for Set 1. Figure 4 (panel A) and Figure 8 presents these angle distributions for **13** and **27**. Similar to the results for  $K_m$ , all conformational descriptors except angles GS-O3-AA and GS-O7-AA exhibited negative linear coefficients for the OC, as expected since similarity to **13** promoted lower  $K_m$ / norm $V_{max}$  value. Angles GS-O3-AA and GS-O7-AA had positive coefficients in Set 1, but showed almost no change in compound sampling patterns (Table S6) and poor  $r^2$ .

Amongst the structural descriptors, OCs of angles O7-C19-GS and O7-C18-GS yielded the two highest correlations in single variable regression analysis for Set 2. Angle distributions for **13** and **18** are shown in Figure S1. All structural descriptors, except for C19-GS-O7, AA-GS-O3 and GS-O3-AA, yielded negative coefficient, indicating structural similarity with **13** favors activity (Table S7). The poor  $r^2$  (< 0.005) of C19-GS-O7, AA-GS-O3 and GS-O3-AA indicated that these angles did not influence conjugate uptake efficiency.

#### CSP-SAR Model for K<sub>m</sub>/norm V<sub>max</sub>: Multivariable Regression

Multivariable regression identified 500 candidate models for Set 1 and 465 candidate models for Set 2. In Table 5, the best model for Set 1 yielded  $r^2 = 0.975$  and  $Q^2 = 0.895$ , and showed 28.9% probability of being the best model. In Table 6, the best model for Set 2 yielded  $r^2 = 0.937$  and  $Q^2 = 0.877$ , and showed 24.7% probability of being the best model.

The regression plots of the predicted vs. observed  $K_m$ /norm $V_{max}$  values are shown in Figure 9 for Set 1 and Set 2.

Each  $\Delta G_w$  and SASA appeared in the two top models for Set 1 with negative and positive coefficients, respectively.  $\Delta G_w$  indicated that lipophilicity favored transport efficiency. SASA suggested that bulky ligands disfavored efficiency. Both models also included angle O7-AA-C18, which is the angle involving 7-OH,  $\alpha$ -acid and C18. Its negative coefficients indicated conformational similarity to **13** promoted efficiency. Figure 4 (panel B) depicts O7-AA-C18 distribution for **13** and **27**. The two top models also included either PSA<sub>side</sub> and PSA (Table 5). Higher conjugate polar surface area disfavored efficiency. Similar to  $K_m$  models for Set 1, the standardized coefficients of both models suggested that  $\Delta G_w$  predominated over other descriptors to determine transport efficiency.

The two top models for **Set 2** included HD, SASA, and SASA<sub>side</sub> (Table 6). The positive coefficient of HD indicated that increase in polar character diminished efficiency. The positive coefficient of SASA<sub>side</sub> indicated bulker C-24 side chain disfavored efficiency. In contrast to SASA<sub>side</sub>, the negative coefficient of SASA indicated that overall solvent accessible surface area favored efficiency. However, the standardized coefficients indicate that SASA did not impact efficiency as much as SASA<sub>side</sub>. Each model included either angle O7-AA-C19 or distance C19-AA. Each exhibited a positive coefficient, indicating that similarity with **13** disfavored efficiency, although amongst all the descriptors had the least amount of contribution to the models indicating that activity was mainly explained by physicochemical properties. The predicted  $K_m$ /norm $V_{max}$  values of the conjugates in both sets using their respective best model are shown in Table S9 (supplemental data).

Logarithmic transformed data was also analyzed [i.e.  $\log K_m$  and  $\log(K_m/\operatorname{norm} V_{max})$ ]. Model regression results for  $\log K_m$  for Set 1 and Set 2 are presented in Table S10 and Table S11, respectively (supplemental data). Model regression results for  $\log(K_m/\operatorname{norm} V_{max})$  for Set 1 and Set 2 are presented in Table S12 and Table S13, respectively (supplemental data). Results from logarithmic transformed data agreed with non-logarithmic transformed data analysis, in that increased hydrophobicity enhanced activity. Figure S2 (supplemental data) shows predicted versus observed  $\log K_m$  for Set 1 and Set 2. Figure S3 (supplemental data) shows predicted versus observed  $\log(K_m/\operatorname{norm} V_{max})$  for Set 1 and Set 2.

#### Conclusion

hASBT is a prodrug target to increase the absorption of drug candidates that otherwise are insufficiently orally absorbed. The objective was to derive a CSP-SAR model for hASBT uptake, since 3D-QSAR models for ASBT substrates are lacking. A congeneric series of 32 aniline and aminopiperidine bile acid conjugates were evaluated. Twenty-seven compounds were substrates. Five were non-substrates. Mono-anionic conjugates were potent substrates, with  $K_m$  in the same range as  $K_m$  of native bile acids, and thus supporting C-24 conjugation as a prodrug approach. Among the substrates, ring substituents that increased polarity led to a slight decrease in affinity. Electronic character did not significantly impact affinity. Only monoanions were potent substrates, with preference for the negative charge to be proximal to C-24 for active hASBT uptake. None of the three aminopiperidine conjugates (one cation and two zwitterions) were substrates, although were potent inhibitors. Only one of the three dianionic conjugates was a substrate, but was a weak substrate. Translocation across hASBT is a more elaborate and complex phenomenon than binding to hASBT, such that compounds which were strong inhibitors of ASBT were not found to be strongly translocated if not bearing a single negative charge.

CSP-SAR models successfully explained substrate affinity (i.e.  $K_m$ ) and  $K_m$ /norm $V_{max}$ , which is the inverse of substrate efficiency. Since  $K_m$  data for compounds 26 and 27 were around 400-600 fold higher than the rest of the compounds, two parallel sets of analysis were performed; one set included all substrates (Set 1), while the other set excluded 26 and 27 (Set 2). Single variable linear regression analysis showed that physicochemical properties of these compounds yielded better correlation with the various kinetic parameters than the conformational descriptors. Both  $K_m$  and  $K_m$ /norm $V_{max}$  yielded successful CSP-SAR models for both sets of compounds. The best CSP-SAR model for  $K_m$  included two structural and two physiochemical descriptors, where substrate hydrophobicity enhanced affinity. The best CSP-SAR model for  $K_m$ /norm $V_{max}$  in both Set 1 and Set 2 employed one structural and three physicochemical descriptors, indicating hydrophobicity enhanced efficiency. Notably, the difference in the quality of model fit and the predictive power of the best models between Set 1 and Set 2 was less than 0.105 showing that CSP-SAR method was able to develop robust models for both set of compounds. CSP-SAR models for the substrate requirements were overall guided by conjugate hydrophobic and polar characteristics.

#### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

#### Abbreviations

hASBT	Human apical sodium-dependent bile acid transporter
CDCA	Chenodeoxycholic acid
CSP	Conformationally sampled pharmacophore
3D-QSAR	three dimensional structural acivity relationship
MD	Molecular dynamics
PSA	Polar surface area
HD	Hydrogen bond donor
OC	Overlap coefficient
SASA	Solvent accessible surface area
MR	Molar refractivity
MDCK	Madin Darby canine kidney

#### Acknowledgments

This work was support in part by National Institutes of Health grants DK67530 and the Computer-Aided Drug Design Center, University of Maryland, Baltimore for computational resources.

#### REFERENCE

- Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009; 50:2340–2357. [PubMed: 19498215]
- St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ. Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol. 2001; 204:1673–1686. [PubMed: 11316487]
- Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch. 2004; 447:566–570. [PubMed: 12851823]

- Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007; 24:1803–1823. [PubMed: 17404808]
- Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm. 2006; 3:223–230. [PubMed: 16749855]
- Balakrishnan A, Wring SA, Coop A, Polli JE. Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Mol Pharm. 2006; 3:282–292. [PubMed: 16749860]
- Lack L. Properties and biological significance of the ileal bile salt transport system. Environ Health Perspect. 1979; 33:79–89. [PubMed: 540627]
- Swaan PW, Szoka FC Jr, Oie S. Molecular modeling of the intestinal bile acid carrier: a comparative molecular field analysis study. J Comput Aided Mol Des. 1997; 11:581–588. [PubMed: 9491350]
- Baringhaus KH, Matter H, Stengelin S, Kramer W. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na(+)/bile acid cotransporter. J Lipid Res. 1999; 40:2158–2168. [PubMed: 10588941]
- Balakrishnan A, Wring SA, Polli JE. Interaction of native bile acids with human apical sodiumdependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm Res. 2006; 23:1451–1459. [PubMed: 16783481]
- Bernard D, Coop A, MacKerell AD Jr. 2D conformationally sampled pharmacophore: a ligandbased pharmacophore to differentiate delta opioid agonists from antagonists. J Am Chem Soc. 2003; 125:3101–3107. [PubMed: 12617677]
- Bernard D, Coop A, MacKerell AD Jr. Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity. J Med Chem. 2007; 50:1799–1809. [PubMed: 17367120]
- Bernard D, Coop A, MacKerell AD Jr. Conformationally sampled pharmacophore for peptidic delta opioid ligands. J Med Chem. 2005; 48:7773–7780. [PubMed: 16302816]
- Gonzalez PM, Acharya C, Mackerell AD Jr, Polli JE. Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamylbile acids. Pharm Res. 2009; 26:1665–1678. [PubMed: 19384469]
- Rais RC, Acharya AD, MacKerell JE Jr, Polli JE. Molecular switch controlling the binding of anionic bile acid conjugates by hASBT. J Med Chem. 2009; 53:4749–4760. [PubMed: 20504026]
- Balakrishnan A, Sussman DJ, Polli JE. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res. 2005; 22:1269–1280. [PubMed: 16078136]
- Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE. Method to screen substrates of apical sodiumdependent bile acid transporter. AAPS J. 2008; 10:596–605. [PubMed: 19085111]
- Balakrishnan A, Hussainzada N, Gonzalez P, Bermejo M, Swaan PW, Polli JE. Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther. 2007; 320:133–144. [PubMed: 17038509]
- Brooks BR, Brooks CL III, MacKerell AD Jr, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RV, Woodcock HL, Wu X, Yang W, York DM, Karplus M. CHARMM: The biomolecular simulation program. J. Comp. Chem. 2009; 30:1545–1614. [PubMed: 19444816]
- 20. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, Darian E, Guvench O, Lopes P, Vorobyov I, MacKerell AD Jr. CHARMM General Force Field (CGenFF): A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comp Chem. 2009 (Epub ahead of print).
- Feig M, Karanicolas J, Brooks CL 3rd. MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J Mol Graph Model. 2004; 22:377–395. [PubMed: 15099834]
- 22. Garcia AE, Sanbonmatsu KY. Exploring the energy landscape of a beta hairpin in explicit solvent. Proteins. 2001; 42:345–354. [PubMed: 11151006]

Mol Pharm. Author manuscript; available in PMC 2011 December 6.

Rais et al.

- 23. Sugita Y, Okamoto Y. Replica-exchange Molecular Dynamics Method for Protein Folding. Chem Phys Lett. 1999; 314:141–151.
- 24. Allen, MP.; Tildesley, DJ. Computer simulation of liquids. Oxford: Clarendon Press; 1987. p. 385
- Lee MS, Feig M, Salsbury FR, Brooks CL. New analytic approximation to the standard molecular volume definition and its application to generalized born calculations. Journal of Computational Chemistry. 2003; 24:1348–1356. [PubMed: 12827676]
- Lee MS, Salsbury FR, Brooks CL. Novel generalized Born methods. Journal of Chemical Physics. 2002; 116:10606–10614.
- 27. Ryckaert JP, Ciccotti G, Berendsen JC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. Journal of Computational Physics. 1977; 23:327–341.
- Hawkins, GD.; Giesen, DJ.; Lynch, GC.; Chambers, CC.; Rossi, I.; Storer, JW.; Li, J.; Zhu, T.; Thompson, JD.; Winget, P., et al. AMSOL Version 6.8. Minneapolis, MN: University of Minnesota;
- 29. Lee B, Richards FM. The interpretation of protein structures: estimation of static accessibility. J Mol Biol. 1971; 55:379–400. [PubMed: 5551392]
- 30. Chothia C. Structural invariants in protein folding. Nature. 1975; 254:304–308. [PubMed: 1118010]
- Auffinger P, Hays FA, Westhof E, Ho PS. Halogen bonds in biological molecules. Proc Natl Acad Sci U S A. 2004; 101:16789–16794. [PubMed: 15557000]
- 32. Panigrahi SK, Desiraju GR. Strong and weak hydrogen bonds in the protein-ligand interface. Proteins. 2007; 67:128–141. [PubMed: 17206656]
- Berski S, Ciunik Z, Drabent K, Latajka Z, Panek J. Dominant role of C-Br---N halogen bond in molecular self-organization Crystallographic and quantum-chemical study of schiff-basecontaining triazoles. Journal of Physical Chemistry B. 2004; 108:12327–12332.
- Acharya C, Seo PR, Polli JE, MacKerell AD Jr. Computational model for predicting chemical substituent effects on passive drug permeability across parallel artificial membranes. Mol Pharm. 2008; 5:818–828. [PubMed: 18710255]
- Hanke PR, Timm P, Falk G, Kramer W. Behavior of different suture materials in the urinary bladder of the rabbit with special reference to wound healing, epithelization and crystallization. Urol Int. 1994; 52:26–33. [PubMed: 8140676]
- 36. Discovery Studio, Accelrys Inc. (http://www.accelrys.com/dstudio).
- 37. Schroeder, LD.; Sjoquist, DL.; Stephan, PE. Understanding regression analysis: an introductory guide. Sage Publications; 1986.
- 38. Olobatuyi, ME. A user's guide to path analysis. University Press of America; 2006.
- 39. Akaike H. Likeliood of a Model and Information Criteria. Journal of Econometrics. 1981; 16:3-14.
- 40. McQuarrie, ADR.; Tsai, CL. Regression and Time Series Model Selection. Singapore: World Scientific; 1998.
- 41. Balakrishnan A, Wring SA, Polli JE. Interaction of native bile acids with human apical sodiumdependent bile acid transporter (hASBT): Influence of steroidal hydroxylation pattern and C-24 conjugation. Pharmaceutical Research. 2006; 23:1451–1459. [PubMed: 16783481]

Rais et al.



#### Figure 1.

Structural features in anilinyl conjugates of glu-CDCA used for pharmacophore development. Notation is as follows: O3, position of 3-OH; O7, position of 7-OH; BC, centroid of B and C rings of steroidal nucleus; C18, location of C-18; C19, location of C-19; C20, location of C-20; C-24 is the location of the charge on unconjugated native bile acids; AA, centroid of carboxylic acid oxygens on a-acid; GS, centroid of  $\gamma$ -substituent (R1); R2 is the substituent on the a-acid (-H or -CH2C6H5).

Rais et al.

Page 15



#### Figure 2.

Concentration-dependent uptake profiles. (A) Taurocholate and (B) unsubstituted aniline conjugate were actively translocated by hASBT. Uptake was greater in the presence of sodium ( $\bullet$ ) than in the absence of sodium ( $\circ$ ), indicating them to be hASBT substrates.

Rais et al.



#### Figure 3.

Plotted relationships between substrate and inhibition parameters for conjugates 1–25 (i.e. **Set 1**). (A) The relationship between normalized  $V_{max}$  and  $K_m$  is plotted. Compounds with higher affinity (i.e. lower  $K_m$ ) were associated with higher capacity. (B) The relationship between  $K_m$  and  $K_i$  is plotted. Substrate affinity and inhibitory potency were generally similar, implicating binding as the rate limiting step in overall conjugate translocation. (C) The relationship between normalized  $V_{max}$  and  $K_i$  is plotted. Inhibitor potency and capacity for each conjugate were generally positively associated, as lower  $K_i$  (i.e. higher binding) was associated with higher translocation capacity. The trend between  $K_i$  and normalized  $V_{max}$  was similar to the trend between  $K_m$  and normalized  $V_{max}$  in panel A.

Mol Pharm. Author manuscript; available in PMC 2011 December 6.



#### Figure 4.

Probability distributions of structural descriptors for  $K_m$  modeling of **Set 1**. (A) Angle C19-GS-O3 and (B) angle O7-AA-C18 displayed the two highest single variable correlations amongst all structural descriptors. (C) Angle O7-AA-BC represents spatial orientation of 7-OH,  $\alpha$ -acid and the steroidal nucleus. The red line represents the distribution of **13** (most potent substrate of all compounds) and the blue line for **27** (weakest substrate in **Set 1**). Panels B and C depict the conformational distributions of the topological descriptors in the top two multivariable CSP-SAR models for **Set 1**.

Rais et al.

А



в



#### Figure 5.

Regression plots of predicted vs. observed  $K_m$  values for anilinyl conjugates of glu-CDCA using CSP-SAR. (A) Using **Set 1**, the model yielded  $r^2 = 0.926$  and  $Q^2 = 0.630$ . (B) Using **Set 2**, which excludes compounds **26** and **27** which were the two least potent substrates, the model yielded  $r^2 = 0.821$  and  $Q^2 = 0.683$ .



#### Figure 6.

Probability distributions of structural descriptors for  $K_m$  modeling of Set 2. (A) Angle GS-O3-C18 and (B) angle GS-O7-C18 were the structural descriptors in the best and second best model for Set 2, respectively. Compounds 13 and 18 were the most and least potent substrates in Set 2, respectively.



#### Figure 7.

Representative conformations of compounds 13, 18, and 27. The most potent substrate (13) is shown in red. The least potent substrate (27) of all compounds is shown in green. Compound 18 is shown in blue and is the least potent substrate in Set 2. The  $\gamma$ -substituent of Compound 27 sample distinctive conformations compared to other compounds. Regarding structural conformation, compound 18 was more similar to 13 than was 27.

Mol Pharm. Author manuscript; available in PMC 2011 December 6.



#### Figure 8.

Probability distribution of angle O7-C19-GS. O7-C19-GS was the best structural description from single variable analysis for  $K_m$ /norm $V_{max}$  for **Set 1**. The red line represents the distribution of **13**; the blue line represents the same for **27**.

Rais et al.

А



Observed  $K_m$ / normV<sub>max</sub> ( $\mu$ M)

в



#### Figure 9.

Regression plots of predicted vs. observed  $K_m$ /norm $V_{max}$  values for anilinyl conjugates of glu-CDCA using CSP-SAR. (A) Using Set 1, the model yielded  $r^2 = 0.975$  and  $Q^2 = 0.895$ . (B) Using Set 2, the model yielded  $r^2 = 0.937$  and  $Q^2 = 0.877$ .

## Table 1





Mol Pharm. Author manuscript; available in PMC 2011 December 6.







 $\frac{Pp \times 10^{6}}{(\text{cm/s})^{b}}$ 1.71±0.01

 $3.39\pm0.12$ 

 $0.800 \pm 0.110$ 

 $2.54\pm0.69$ 

ī

Η

C2H500C-

16

17

 $1.59\pm0.07$ 

 $0.203 \pm 0.017$ 

 $10.3 \pm 3.1$ 

T

Η

4 H

 $4.08 \pm 0.28$ 

 $1.47\pm0.31$ 

 $7.27 \pm 2.80$ 

T

Η

COOC<sub>2</sub>H<sub>5</sub>

15

 $1.73\pm0.07$ 

 $0.250 \pm 0.022$ 

 $17.5 \pm 4.7$ 

ī

Н

18



1.00+0.05

 $1.45 \pm 0.06$ 

 $1.42 \pm 0.02$ 

 $0.667 \pm 0.031$  $\frac{Pp \times 10^6}{(\mathrm{cm/s})^b}$ 

Mol Pharm. Author manuscript; available in PMC 2011 December 6.

Ê,





 $^{b}\mathrm{P}_{p}$  is the passive permeability of the conjugates.

Mol Pharm. Author manuscript; available in PMC 2011 December 6.

\_

#### Table 2

Conjugates that were non-substrate for ASBT.  $R_1$  and  $R_2$  refer to substituents on the same general structure in Table 1.

Compound	<b>R</b> <sub>1</sub>	<b>R</b> <sub>2</sub>	Charge	Pp × 10 <sup>6</sup> (cm/s)
28	соон	Н	-2 (Dianion)	0.216±0.012
29	ноос	Н	-2 (Dianion)	0.104±0.005
30	HN	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	+1 (Cation)	4.71±0.09
31	HN	Н	zwitterion	0.204±0.023
32		Н	zwitterion	0.336±0.017
	−−N −ξ			

_
_
_
- U
-
-
_
<u> </u>
-
<u> </u>
-
$\mathbf{O}$
$\mathbf{U}$
_
_
-
>
0
2
_
_
_
<u> </u>
U)
Ö
0
<u> </u>
()
<u> </u>

Rais et al.

# Table 3

Results from multivariable regression and AIC<sub>C</sub> analysis for the selected CSP-SAR models for  $K_m$  for Set 1.<sup>*a*</sup>

CSP-SAR Models	r <sup>,2</sup>	$Q^2$	${f F}$	$W_i$	<i>К</i> (µМ)	A (μM/ kcal/mol)	В (µЛ)	C (µM/m <sup>3</sup> /mol)	(Мц)	Standardized A (µM/ kcal/mol)	Standardized B (μM)	Standardized C (μΜ/ m <sup>3</sup> /mol)	Standardized $D(\mu M)$
ΔG <sub>w</sub> , O7-AA-C18, MR, BC-GS <sub>min</sub>	0.926	0.630	66.1	10.8	-1460 $\pm 217$	$-6.59 \pm 0.58$	-630 $\pm 137$	72.4 ± 11	$\begin{array}{c} 327 \pm \\ 104 \end{array}$	-0.780	-0.456	0.390	0.329
ΔG <sub>w</sub> , O7-AA-BC, MR, O7-GS <sub>min</sub>	0.926	0.633	60.3	10.4	$\begin{array}{c} -  1488 \\ \pm  214 \end{array}$	- 6.89 ± 0.60	- 591 ± 129	73.1 ± 11	$\begin{array}{c} 295 \pm \\ 103 \end{array}$	-0.816	-0.413	0.394	0.288

 $^{a}$ , B, C and D represent the coefficient of the independent variables (molecular descriptors); K represents the coefficient of the intercept; Q<sup>2</sup> represents the cross validated r<sup>2</sup>; F is the test statistic value from the F-test regarding the significance of the model; Wi is percent probability of the model being the best model; Set 1 includes all compounds that were substrates. **NIH-PA Author Manuscript** 

# Table 4

Results from multivariable regression and AIC<sub>C</sub> analysis for the selected CSP-SAR models for  $K_m$  for Set 2.<sup>a</sup>

CSP-SAR Model	<b>1</b> 2	${f 0}^{7}$	F	$W_i$	<i>К</i> (µМ)	А (MI)	<i>В</i> (µМ)	С	D	Standardized A (µM)	Standardized Β (μΜ)	Standardized C	Standardized D
HD, KierFlex, ΔG <sub>w</sub> , GS-03-C18	0.821	0.683	21.7	13.5	- 99.3 ±17	$\begin{array}{c} 8.03 \pm \\ 1.3 \end{array}$	$5.10\pm$ 1.1	- 0.556 ± 0.184 (μM/kcal /mol)	– 23.2 ± 6.7 (μM)	0.662	0.457	–0.397 (μM/kcal /mol)	-0.438 (μM)
HD, GS-07-C18, KierFlex, $\Delta G_{w}$	0.809	0.673	20.1	6.35	-96.7 $\pm 17$	7.74 ± 1.4	$\begin{array}{c} - & 18.6 \\ \pm & 5.8 \end{array}$	5.10± 1.2 (μM)	<ul> <li>- 0.483 ±</li> <li>0.18</li> <li>(μM/kcal /mol)</li> </ul>	0.639	-0.401	0.456 (µM)	-0.344 (μM/kcal /mol)

<sup>4</sup>*A*, *B*, *C* and *D* represent the coefficient of the independent variables (molecular descriptors); *K* represents the coefficient of the intercept. Set 2 includes all compounds that were substrates, except the 26 and 27, which were weak substrates.

**NIH-PA Author Manuscript** 

# Table 5

Results from multivariable regression and AIC<sub>C</sub> analysis for the selected CSP-SAR models for K<sub>m</sub>/normV<sub>max</sub> for Set 1.<sup>a</sup>

Standardized D (μΜ/Å <sup>2</sup> )	0.249	0.081
Standardized C (μM/Å <sup>2</sup> )	0.087	0.247
Standardized B (μM)	-0.296	-0.307
Standardized A (µM/kcal/mol)	-0.868	-0.869
D (µМ/Å <sup>2</sup> )	$0.835 \pm 0.13$	$\begin{array}{c} 0.554 \pm \\ 0.26 \end{array}$
С (µМ/Å <sup>2</sup> )	$0.600 \pm 0.25$	$\begin{array}{c} 0.828 \pm \\ 0.14 \end{array}$
B (µM)	$-535 \pm 77$	-556 $\pm 82$
A (μM/kcal/mol)	− 9.61 ± 0.42	- 9.62 ± 0.44
К (µМ)	- 1210 ± 140	- 1218 ± 148
$W_i$	28.9	15.1
${F}$	207	197
${oldsymbol{o}}^{_{2}}$	0.895	0.867
7	0.975	0.974
CSP-SAR Model	ΔG <sub>w</sub> , O7-AA-C18, PSA <sub>side</sub> , SASA	ΔG <sub>w</sub> , O7-AA-C18, SASA, PSA

<sup>a</sup>A, B, C and D represent the coefficient of the independent variables (molecular descriptors); K represents the coefficient of the intercept. Set 1 includes all compounds that were substrates.

# Table 6

Results from multivariable regression and AIC<sub>C</sub> analysis for the selected CSP-SAR models for K<sub>m</sub>/normV<sub>max</sub> for Set 2.<sup>a</sup>

Rais et al.

CSP-SAR Model	r <sup>2</sup>	$Q^2$	${f F}$	$W_i$	<i>К</i> (µМ)	$^{A}_{(\mu M)}$	$B \ (\mu M/ { m \AA}^2)$	$C_{(\mu M/\AA^2)}$	D (MJ)	Standardized A (μM)	Standardized Β (μΜ/Å <sup>2</sup> )	Standardized C $(\mu M/{\rm \AA}^2)$	Standardized D (μM)
HD, SASA <sub>side</sub> , SASA, 07-AA-C19	0.937	0.877	71.1	24.7	$^-$ 71.9 $\pm$ 29	26.7 ± 2.6	$0.454\pm 0.061$	$\begin{array}{c} - \ 0.346 \\ \pm \ 0.077 \end{array}$	70.7 ± 23	0.629	1.24	-0.976	0.432
HD, SASA <sub>side</sub> , SASA, C19-AA	0.936	0.884	69.69	19.4	$^{- 83.2}_{\pm 28}$	27.8 ± 2.7	$0.422 \pm 0.054$	$-$ 0.313 $\pm 0.069$	$\begin{array}{c} 63.5 \\ \pm \ 21 \end{array}$	0.656	1.15	-0.884	0.379

 $^{a}$ , B, C and D represent the coefficient of the independent variables (molecular descriptors); K represents the coefficient of the intercept. Set 2 includes all compounds that were substrates, except the 26 and 27, which were weak substrates